Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
87.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.00 (5.882%)
Market Cap: £5.75m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Contract Win

9 Apr 2010 07:00

RNS Number : 9258J
Crimson Tide PLC
09 April 2010
 



09 April 2010

Crimson Tide Plc

("Crimson Tide" or the "Company")

SMARTPHONE SYSTEM FROM CRIMSON TIDE EXTENDS BLOOD SAFETY SYSTEM TO PATIENTS' HOMES

Crimson Tide, the AIM quoted mobile data solutions provider, has signed a four year contract, worth up to €100,000 a year, for an advanced hand held system, mpro3hx, that enables Europe's first bar code safety system for blood disorder sufferers to be used at the patient's home. The contract, with Temperature Control Pharmaceuticals Limited (TCP) based in Dublin, is for up to 179 hand held units and is part of the National Haemophilia Project in Ireland.

The mobile software has been specifically designed by Crimson Tide and will run on a range of Windows Mobile™ smartphones supplied to the end user. Crimson Tide is a Microsoft Gold Certified Partner.

Says Crimson Tide's Executive Chairman Barrie Whipp: 'In terms of user numbers multiplied by length of contract this is our largest subscription deal to date. Our application is relevant to in-home patient drug administration worldwide , therefore we are anticipating extending our sales of this type of product in other marketplaces and for other patient uses.'

Derek McCormack, Managing Director of TCP said "TCP are delighted to work with Crimson Tide to roll out the Patient Handheld Devices for home treatment haemophiliapatients. They will help to further improve the quality service provided by TCP to home patients in Ireland."

The industry standard GS1 track-and-trace bar code system has been in use since 2005. It was devised as a result of a medical disaster in the 1980's in which contamination of blood products in Ireland led to 78 deaths when 200 haemophiliacs became infected with HIV and Hepatitis C.

With the new GS1 system, globally unique IDs assigned for each patient, product and location facilitate the automatic linking, capture and processing of data across the supply chain. Once a prescription is received for a patient or hospital delivery, all picking, packing and shipping is performed using barcode scanning, enabling each step in the cold chain delivery process to be validated.

Crimson Tide's innovation extends this traceability to the precise point of administration in the patient's home. Using the patient's mobile phone, the Company's system verifies the product ID (GTIN, batch/lot number, expiry date and serial number) before self-treatment is carried out. It can be used to alert patients of product recalls and, where there is more than one haemophilia patient in a household on different treatment, it ensures the right patient is treated with the right Coagulation Factor Concentrate (CFC) product.

In Ireland there are around 2,000 patients who suffer from some form of bleeding disorder, 200 of whom suffer from the severe type of haemophilia that requires intensive treatment, which means they self-medicate at home, work, school or on holiday. Crimson Tide's solution ensures that the right medication is administered at the right time, to the right patient in the right dose, by the right route.

Windows Mobile is a registered trademark of Microsoft Corporation in the United States and other countries.

- ends -

For further information, contact:

Crimson Tide plc

Barrie Whipp, Executive Chairman

 

01892 542 444

Threadneedle Communications

Graham Herring/Josh Royston

 

020 7653 9850

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGURCCUPUGAR
Date   Source Headline
30th Jun 202011:53 amRNSResult of AGM and Trading Update
15th Jun 202010:42 amRNSSignificant Contract Win
9th Jun 20204:06 pmRNSAnnual Report and Notice of AGM
7th May 20207:11 amRNSPreliminary Results
4th May 20204:05 pmRNSDIRECTOR RESIGNATION
1st Apr 20203:30 pmRNSHolding(s) in Company
30th Mar 20207:00 amRNSStatement regarding Coronavirus
13th Mar 20207:00 amRNSChange of Adviser
25th Feb 20208:19 amRNSHolding(s) in Company
18th Feb 20207:00 amRNSSignificant contract wins in the rail sector
28th Jan 202010:43 amRNSHolding(s) in Company
3rd Jan 20209:17 amRNSHolding(s) in Company
23rd Dec 20197:00 amRNSSignificant long-term contract and trading update
1st Oct 20197:00 amRNSSignificant long-term contract win
27th Sep 20197:00 amRNSInterim Results
1st Jul 20197:00 amRNSDirector and Company Secretary Appointment
28th Jun 20193:02 pmRNSResult of AGM
27th Jun 20197:00 amRNSContract Wins and New Partnerships
7th Jun 20197:00 amRNSFinal Results and Notice of AGM
17th May 20197:00 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSPreliminary Announcement of Results to 31/12/18
16th Apr 20199:20 amRNSHolding(s) in Company
1st Mar 20192:56 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSContract Wins in the rail sector
29th Jan 20197:00 amRNSTrading Update
2nd Nov 20182:08 pmRNSExercise Of Options
4th Oct 20184:47 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSInterim Results
20th Sep 20187:00 amRNSContract Wins and Recruitment
5th Jul 20188:38 amRNSmpro5 healthcare update
2nd Jul 201811:21 amRNSResult of AGM
7th Jun 20188:28 amRNSFinal Results and Notice of AGM
24th Apr 20187:00 amRNSChange of Adviser
13th Apr 20187:00 amRNSPreliminary Results to 31 December 2017
28th Mar 20187:00 amRNSAppointment of new CEO
27th Feb 20187:00 amRNSTrading Statement
19th Dec 20173:44 pmRNSDirector/PDMR Shareholding
15th Dec 201711:30 amRNSExercise of Options
8th Dec 20173:37 pmRNSResult of GM
23rd Nov 20177:00 amRNSNotice of GM
24th Oct 20177:00 amRNSSeries of contract wins for mpro5
17th Oct 20177:00 amRNSDirectorate Change
7th Sep 20177:00 amRNSInterim Results
11th Jul 20177:00 amRNSSignificant mpro5 Contract Win in the Netherlands
29th Jun 20175:47 pmRNSResult of AGM
6th Jun 20172:00 pmRNSFinal Results and Notice of AGM
30th May 20177:00 amRNSInternational Expansion Update
30th Mar 20177:00 amRNSPreliminary Results
2nd Feb 20177:00 amRNSUpdate on International Expansion
14th Dec 20167:00 amRNSTrading Update and Contract Rollout

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.